Table 2.
irAEs with CTLA-4 + PD-1 blockade |
irAEs with anti-PD-1 resumption (recurrent or de novo) |
|||
---|---|---|---|---|
irAE | All grade irAE, n (%) | Grade 3/4 irAE, n (%) | All grade irAE, n (%) | Grade 3/4 irAE, n (%) |
Colitis | 33 (41) | 20 (25) | 6 (8) | 2 (3) |
Hepatitis | 29 (36) | 19 (24) | 8 (10) | 5 (7) |
Hypophysitis | 5 (6) | 2 (3) | 2 (3) | 1 (1) |
Dermatitis/rash | 5 (6) | 3 (4) | 6 (8) | 2 (3)a |
Pneumonitis | 3 (4) | 1 (1) | 4 (5) | – |
Elevated lipase | 4 (5)b | 4 (5) | 3 (5) | 2 (3)b |
Nephritis | 2 (3) | 1 (1) | 1 (1) | – |
Neurologic | 2 (3) | 1 (1) | – | – |
ITP | 1 (1) | 1 (1) | – | – |
Other | 7 (9) | 2 (3) | 8 (10) | 2 (3)c |
Includes one patient with grade 5 Stevens–Johnson Syndrome.
Two patients with clinical pancreatitis.
Grade 3 type 1 diabetes and grade 3 arthralgias.
CTLA-4, cytotoxic T-lymphocyte antigen 4; PD-1, programmed death 1; irAE, immune-related adverse event.